Hi guys, this might be old news, but doing a bit of research today I came across this analysis by Edison Research of Destiny Pharma in the UK.
https://www.edisongroup.com/wp-content/uploads/2018/10/Destiny-Pharma-Destiny-beguiles-1.pdf
Destiny have just finished a Phase 2 trial (results Q1) of a drug similar to ours for prevention of post operative infections (yes i know, competition).
I found the analysis interesting because it gives some assumptions of potential earnings if all goes well.
Sorry if this has been posted before.
BOT - Anything but charting, page-1441
-
- There are more pages in this discussion • 8,633 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
40.0¢ |
Change
0.050(14.3%) |
Mkt cap ! $724.0M | |||
| Open | High | Low | Value | Volume |
| 35.5¢ | 40.0¢ | 35.5¢ | $6.075M | 15.87M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 287187 | 39.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 40.0¢ | 1920397 | 33 |
View Market Depth
| Last trade - 16.10pm 30/08/2024 (20 minute delay) ? |
| BOT (ASX) Chart |